This article may rely excessively on sources too closely associated with the subject, potentially preventing it from being verifiable and neutral. (January 2026) |
Schelto Kruijff is a Dutch surgical oncologist and academic researcher, a professor of surgery affiliated with the University Medical Center Groningen (UMCG) and the University of Groningen (RUG). His work focuses on surgical oncology, the use of fluorescence-guided surgery, endocrine tumor treatment, and sustainability in healthcare.[1][2]
Education
editIn 2011, Kruijff earned a Doctor of Philosophy (PhD) degree at the University of Groningen, where his doctoral dissertation focused on biomarkers in melanoma.[3] Following his doctorate, he completed postdoctoral training, including a TS Reeve Endocrine Surgery Fellowship at the University of Sydney, Australia.[4] He later undertook additional fellowship experience in hepatobiliary surgery after returning to the Netherlands.[3] Prior to his doctoral studies, he completed a surgical residency in abdominal and oncological surgery.[3]
Career
editKruijff holds a position as staff consultant in surgical oncology and endocrine surgery at the University Medical Center Groningen and is affiliated with the University of Groningen.[2][1] He is also affiliated with Karolinska Institutet in Sweden, where he participates in research activities within molecular medicine and surgical sciences.[5] His clinical practice includes the surgical treatment of endocrine tumors, such as thyroid and adrenal gland tumors, as well the treatment of adrenal tumors.[2] He serves as head researcher of the Optical Molecular Imaging Group (OMIG), a multidisciplinary research group in Groningen that develops targeted and non-targeted fluorescence-guided techniques for surgical applications.[4]
Kruijff has held roles in professional and academic organizations, including board membership of the Dutch Association of Oncological Surgery (NVCO).[6] He was appointed Chief Green Officer of UMCG, a role focused on promoting sustainability and reducing the environmental impact of healthcare delivery.[7][8]
Research
editKruijff's research covers surgical innovation, oncological outcomes, imaging techniques, and perioperative technologies. His work includes studies on fluorescence-guided surgery and optical imaging in thyroid and parathyroid procedures, as well as translational and clinical research in cancer care.[9]
He has contributed to academic and public discussions on sustainable innovation in surgery and healthcare systems, including lectures and media interviews addressing environmentally responsible medical practice.[10]
Selected publications
edit- Studies on quantitative near-infrared fluorescence imaging using indocyanine green in surgical settings.[9]
- Research on PET/CT imaging in medullary thyroid cancer to support surgical decision-making.[9]
- Investigations into intestinal and parathyroid perfusion measurement techniques.[9]
- Early clinical research on melanoma biomarkers.[11]
References
edit- 1 2 "S. Kruijff". University of Groningen. Retrieved 30 December 2025.
- 1 2 3 "S. Kruijff". University Medical Center Groningen. Retrieved 30 December 2025.
- 1 2 3 "Curriculum vitae – S. Kruijff". University of Groningen. Retrieved 30 December 2025.
- 1 2 "Schelto Kruijff". Optical Molecular Imaging Group. Retrieved 30 December 2025.
- ↑ "Schelto Kruijff". Karolinska Institutet. Retrieved 30 December 2025.
- ↑ "S. Kruijff". UMCG Research. Retrieved 30 December 2025.
- ↑ "UMCG stelt Schelto Kruijff aan als Chief Green Officer". Skipr. Retrieved 30 December 2025.
- ↑ "UMCG benoemt Schelto Kruijff tot Chief Green Officer". Duurzaam Ondernemen. Retrieved 30 December 2025.
- 1 2 3 4 "Schelto H. Kruijff". ScienceDirect. Retrieved 30 December 2025.
- ↑ "Sustainable innovation with a green operation". Keendoc. Retrieved 30 December 2025.
- ↑ Kruijff, Schelto (2011). Nodal metasases and biomarkers in melanoma. Groningen: [s.n.] ISBN 978-90-367-5180-3.